ZBiotics, a company that is creating a new category of genetically engineered probiotics, announced the closing of its $12 million Series A funding round, led by Spring Tide Capital. The oversubscribed round also includes participation by Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures.
The company will use the funding to meet growing consumer demand, spearhead retail expansion, and drive continued research and development in a new sector, including bringing new genetically engineered probiotic products to market that address the unique and newly arising biological challenges of modern living.
Led by a team of Ph.D. scientists passionate about bringing new functionality to the human body and augmenting existing functions, ZBiotics utilizes a new kind of genetic engineering: transparent, responsible, and built directly for consumers. Utilizing modern biotechnology, the company helps consumers actively engage in living healthier lives by creating genetically engineered probiotics for specific use cases that solve modern-day, real-world problems.
The company’s flagship product – which is a Pre-Alcohol Probiotic Drink – mimics the function of the liver by breaking down the toxic byproduct of alcohol, acetaldehyde, helping consumers feel better the day after drinking.
ZBiotics combines biotechnology with consumer goods to solve problems that previously only had band-aid solutions. Driven by the mission of making people healthier through modern biotechnology, ZBiotics has created a company that provides consumers with sustainable, effective solutions that cannot and do not exist without genetic engineering.
ZBiotics will use the funding from its Series A round to develop and bring additional use-case probiotics to market. It will utilize the same technology used to develop its Pre-Alcohol Probiotic Drink to create additional solutions for consumers looking to prioritize different aspects of their health.
Along with its flagship product, the company will launch its second product in the coming weeks, focusing on microbial diversity in the gut and associated benefits. The research and development at ZBiotics actively explores products that will address a range of concerns like sleep, vaginal health and athletic performance. The funds will also be used to launch the ZBiotics brand into physical retail spaces, aligning with the company’s long-term vision to make “proudly GMO” products more accessible to the consumers who benefit from their solutions.
KEY QUOTES:
“Genetic engineering allows us to make totally new products that address real-world consumer needs, and we’re witnessing a growing interest in our technology and brand. In a market that craves real solutions, we’ve shown that being a proudly GMO company prioritizing transparency resonates with consumers, driving ZBiotics’ momentum. With these funds, we aim to meet demand and expand the ZBiotics product line beyond our flagship product.”
- Zack Abbott, Ph.D., co-founder and CEO of ZBiotics
“Off of the breakout success of their first product, ZBiotics has more than doubled sales every year, selling over 5 million units cumulatively and reaching company-wide profitability in 2023. We are thrilled to support the team as they continue to expand their revolutionary probiotic platform across many more exciting use cases that address everyday consumer pain points.”
- Adam Ramada, co-managing partner of Spring Tide Capital
